Provectus Biopharmaceuticals Capital Expenditures (CapEx) Growth & History (PVCT)
Provectus Biopharmaceuticals's capital expenditures (capex) was $30,400 for fiscal 2017.
View full Provectus Biopharmaceuticals company overviewProvectus Biopharmaceuticals annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2017 | 2017-12-31 | $30,400 | — | — |
| 2015 | 2015-12-31 | $6,139 | −$64,451 | −91.30% |
| 2014 | 2014-12-31 | $70,590 | $63,940 | +961.50% |
| 2013 | 2013-12-31 | $6,650 | −$9,235 | −58.14% |
| 2012 | 2012-12-31 | $15,885 | $9,738 | +158.42% |
| 2011 | 2011-12-31 | $6,147 | — | — |
| 2009 | 2009-12-31 | $5,839 | — | — |
Provectus Biopharmaceuticals quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q4 2012 | 2012-12-31 | $0 | — | — |
| Q3 2012 | 2012-09-30 | $0 | $0 | — |
| Q2 2012 | 2012-06-30 | $0 | — | — |
| Q1 2012 | 2012-03-31 | $15,885 | — | — |
| Q3 2011 | 2011-09-30 | $0 | — | — |
Provectus Biopharmaceuticals capital expenditures (capex) trends
Over the last five fiscal years, Provectus Biopharmaceuticals's capital expenditures (capex) increased from $15,885 to $30,400, a change of $14,515. The latest reported quarter, Q4 2012, shows $0.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Provectus Biopharmaceuticals source filings ↗